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Abstract
Background: Patients with advanced disease experience high levels of psychological distress, yet there is low
uptake of psychosocial services offered to patients who screened positive for distress. In this study we aimed to
identify predictors for use of psychosocial services in patients with metastatic colorectal cancer (mCRC) receiving
first line chemotherapy enrolled in a prospective cluster randomized trial (CRT).
Methods: Patients completed measures on psychological distress, physical distress, and quality of life at baseline.
Demographics, clinical characteristics at baseline and clinical events during treatment (e.g. severe adverse events,
clinical benefit) were extracted from patient records. Patients reported psychosocial service utilization in- and
outside the hospital after 10, 24 and 48 weeks of treatment. Multivariable logistic regression models were used to
identify predictors for the use of psychosocial services.
Results: Out of 349 patients, seventy patients (20.0%) used psychosocial support services during the follow-up
period. Use of psychosocial services was associated with younger age, a higher educational level, presence of more
pain (at baseline), and the expressed need to talk to a professional (at baseline). In addition, patients without
progressive disease within the first ten weeks of treatment were more likely to use psychosocial services .
Conclusions: One in five patients with mCRC receiving first line palliative treatment used psychosocial services
during this prospective longitudinal CRT. Sociodemographic factors (age, education), clinical factors (pain and no
progressive disease) and the expressed need to talk to a professional predicted use of psychosocial services.
Identification of these predictors may contribute to the understanding of factors that determine the need for
psychosocial services.
Trial registration: Netherlands Trial Register NTR4034.
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Background
Over the past decades, research has demonstrated the
considerable emotional impact that colorectal cancer
(CRC) and its treatment can have on patients [1].
Self-reported psychological distress occurs in approxi-
mately one third of CRC patients [2–5]. Patients with
advanced disease seem to be even more susceptible to
develop symptoms of psychological distress [6]. A higher
level of psychological distress is associated with lower
quality of life (QOL), non-adherence to therapy, and
poorer prognosis [7–9]. A variety of psychological inter-
ventions have been shown to be effective in reducing
symptoms of distress and improving QOL [10]. As a re-
sult, current guidelines for cancer care have recom-
mended to routinely screen for psychological distress
and to subsequently offer treatment to those scoring
above the cut off for distress [11].
Yet, the majority of patients scoring above the cutoff
for distress decline professional intervention [12–15]. It
seems that the presence of psychological distress does
not necessarily equate to the need of patients for psy-
chosocial support [2, 12, 16–18]. Distress as such does
not seem to be a sufficient reason to use psychosocial
services, as many patients scoring above the cut off for
distress decline these services. Therefore, instead of as-
suming that all distressed patients need psychosocial ser-
vices, it seems important to take one step back and to
compare patients who use services against those who do
not. Knowledge on factors related to the actual use of
psychosocial services may contribute to our understand-
ing of the factors that determine the need for psycho-
social services. We aimed to identify predictors for use
of psychosocial services in patients with mCRC receiving
first line treatment. Potential predictors included demo-
graphic, clinical, and psychosocial factors at baseline and
clinical factors during treatment.
Methods
This paper reports on a secondary analysis on data ob-
tained in the TES trial (Targeted selection, Enhanced
care, Stepped care trial). In this trial the effectiveness of
a combined screening and treatment program to im-
prove psychological distress compared with care as usual
was evaluated (Netherlands Trial Register (NTR4034)
[19]. The study was approved by the Medical Ethics
Committee of VU University Medical Center (2013/10).
Analyses are based on 349 outpatients with a confirmed
diagnosis of mCRC starting first line systemic treatment
who met the eligibility criteria, recruited throughout 16
hospitals in the Netherlands, between July 2013 and Oc-
tober 2016. All patients provided written informed con-
sent. A description of the study protocol and results of
the original trial have been published previously [14, 19].
In brief, there were no significant differences in course
of distress between the treatment arms. Further, no dif-
ferences in recognition and management of distress or
use of psychosocial support between groups were found,
although satisfaction with care and cognitive functioning
were significantly better in the intervention group.
Outcome and measurements
Demographic and clinical characteristics were obtained
from patients and medical charts at baseline, i.e. start of
first line systemic treatment. In addition, during the 48
weeks of the TES study, information on clinical events
was collected. At baseline, patient-reported psychological
characteristics were measured with the following tools.
The HADS (Hospital Anxiety and Depression Scale) and
DT/PL (Distress Thermometer and corresponding Prob-
lem List) were used to assess distress and the need for
referral with a recall period of two weeks, respectively.
The HADS consist of 14 questions with scores ranging
from 0 to 42, the recommended cut off score for distress
in cancer patients is ≥13 [20]. The DT/PL comprises of
the Distress Thermometer ranging from 0 to 10,
followed by a list of problems evaluating a wide range of
problems and a single question evaluating the need to
talk to a professional [2]. A score of 5 or higher on the
DT has been shown to indicate presence of distress [2].
QOL was measured by the EORTC-QLQ-C30 version
3.0 [21], consisting of five functional scales (physical,
role, cognitive, emotional, and social), symptom scales
and individual symptom items, and perceived financial
impact of the disease.
During treatment, the following clinical events were
assessed by clinicians: treatment modification or discon-
tinuation, clinical benefit during the first 10 weeks of
treatment (progression vs stable disease or partial re-
sponse), occurrence of severe (i.e. grade III/IV) adverse
events (AEs, these were graded and assigned by clini-
cians using the National Cancer Institute’s Common
Terminology Criteria for Adverse Events (NCI-CTCAE)
as mild (Grade 1), moderate (Grade 2), severe (Grade 3),
or life-threatening (Grade 4) [22]) and total number of
unscheduled admissions. Psychosocial service utilization
in- and outside the hospital was assessed using an
adapted version of the TiC-P questionnaire [23] after 10,
24 and 48 weeks of treatment with a recall period of
three months. The TiC-P is a feasible and reliable instru-
ment for collecting data on medical consumption and
productivity losses [23, 24]. The first part of the TiC-P
includes 14 structured yes/no questions on relevant
medical resource items each followed by a question on
the volume of medical consumption. The questions in-
clude contacts within the mental healthcare sector (re-
gional mental healthcare organization, psychiatrist/
psychologist or psychotherapist in private practices or
outpatient hospital, institutional day-care treatment,
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Consultation Agency for Alcohol and Drug addiction
(CAD), self-help group) and contacts with general
healthcare providers (general practitioner, allied health
professional, social worker, providers of alternative medi-
cine, outpatients visits to medical specialists, hospital ad-
mission and contacts with a company doctor) and the
use of medication. For the current analyses we evaluated
contacts with social workers, contacts with services in
regional mental healthcare organizations, contacts with
psychiatrists/psychologists in private practice, and con-
tacts with psychiatrists/psychologist in hospital settings.
Statistical analyses
Descriptive statistics were calculated to summarize all var-
iables and to outline the pattern of use of psychosocial ser-
vices in patients from the TES trial. Differences between
patients who had used psychosocial services versus those
who had not used psychosocial services during follow-up
were computed using the chi-square test for categorical
data and t-test for metric data. Two separate multivariable
analyses were undertaken to identify predictors for the use
of psychosocial support. In the first analysis, baseline vari-
ables potentially related to the use of psychosocial support
were evaluated. Explanatory variables included gender
(male vs female), age at randomization, married/living to-
gether vs living alone, education level (low: primary edu-
cation, middle: lower general secondary education,
intermediate vocational education or high school, high:
higher vocational education or university), employment
(working yes vs no), functional status (defined by the East-
ern Cooperative Oncology Group Performance Status
(ECOG PS), which is a score ranging from zero (“fully ac-
tive”) through three (“capable of only limited self-care”) to
five (“dead”) [25]), right or left sided tumor, number of
prior cancer-related treatments, type of chemotherapy
(capecitabine vs CAPOX vs FOLFOX or other), total
number of (organs with) metastases, time since initial
diagnosis in months (< 1.5months vs 1.5–10months vs >
10months), time since diagnosis of metastatic disease in
months (< 1.0months vs 1.0–2.5months vs > 2.5 months),
comorbidity (number of comorbid conditions as reported
by patients at baseline), allocation to treatment arm of the
parent study (intervention vs control) and participation in
other clinical studies (yes vs no), distress on HADS (score
of < 13 or ≥ 13), distress score on DT (< 5 or ≥ 5), number
of physical problems reported on PL, number of emo-
tional problems reported on PL, need to talk to a profes-
sional (yes vs no), scores on functional QOL scales, global
QOL, fatigue and pain score on EORTC-QLQ-C30. Vari-
ables were included in the multivariable logistic regression
equation if they had an univariable association (p ≤ .25)
with the criterion [26]. A backward stepwise regression
model was computed to select the final model that in-
cluded predictive factors which were statistically
significant at the 0.10 level. Variables not significantly con-
tributing to the multivariable logistic regression equation
were removed. In the second analysis it was evaluated
whether clinical factors during treatment predict use of
psychosocial support. Explanatory variables included clin-
ical benefit during the first 10 weeks of chemotherapy
treatment, number of severe AEs, any severe AE during
treatment, any admission during treatment, and number
of admissions. Using the final model on baseline predic-
tors as a base, variables were included in this model if they
had an univariable association (p ≤ .25) with the criterion.
A backward stepwise regression model was computed to
select the final model that included predictive factors
which were statistically significant at the 0.10 level. Vari-
ables not significantly contributing to the multivariable lo-
gistic regression equation were removed. The explained
variance of the model was assessed by use of Nagelkerke’s
R2. Since multicollinearity can influence the estimated
beta parameter, the variable inflation factor (VIF) for each
variable included in the regression equations was calcu-
lated (i.e. a VIF greater than 2.5 indicates multicollinearity)
[27, 28]. Data were analyzed using IBM SPSS statistics ver-
sion 22.0 (IBM Corp., Armonk, NY).
Results
The sample consisted of all 349 patients enrolled in the
TES study [14]. Table 1 contains sample characteristics.
The 349 patients ranged in age from 23 to 83 years at
diagnosis (mean age 66.1 ± 10.2 years); 224 (64.2%) were
male, 256 (73.4%) were married/living with a partner, 93
(26.7%) scored above the cutoff for distress (measured
with the HADS), and 34 (9.7%) expressed a need to talk
to a professional. At the time of baseline assessment all
patients were receiving chemotherapy, 72 patients
(20.6%) monotherapy, 274 (78.5%) an oxaliplatin-based
combination regimen; for 3 patients type of chemother-
apy was unknown. All treatments were administered
with palliative intent. Seventy (20.0%) out of 349 patients
made use of psychosocial services during the 48-week
follow-up period. Of these, 36 (51.4%) had contact with
social workers, 6 (8.6%) had contact with services in re-
gional mental healthcare organizations, 13 (18.6%) had
contact with psychiatrists/psychologists in private prac-
tices, 4 (5.7%) had contact with psychiatrists/psycholo-
gists in the hospital setting and the remaining 27
patients (38.6%) had contact with multiple psychosocial
services. Twenty-six of 93 (28.4%) patients who scored
above the cutoff for distress on the HADS at baseline
used psychosocial services during the 48-week follow-up
period. Twelve of 34 (35.3%) patients who had expressed
a need to talk to a professional, used psychosocial ser-
vices during the 48-week follow-up period.
Table 1 contains the univariable analyses for baseline
sociodemographic, clinical and psychological factors and
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Table 1 Results of univariable analyses on demographic, clinical and psychosocial baseline variables
No use of psychosocial support
services (n = 279)(n,%)
Use of psychosocial support
services (n = 70)(n,%)
p-value
Age, years *0.003
Mean age (SD) 66.92 (9.7) 62.74 (11.41)
Gender 0.415
Male 182 (65.2) 42 (60.0)
Female 97 (34.8) 28 (40.0)
Treatment arm in TES trial 0.610
Intervention 149 (53.4) 35 (50)
Control 130 (46.6) 35 (50)
ECOG PSa 0.714
0 67 (24.0) 15 (21.4)
1 87 (31.2) 18 (25.7)
2 8 (2.9) 3 (4.3)
Missing 117 (41.9) 34 (48.6)
Primary tumor location 0.695
Right-sided 84 (30.1) 23 (32.9)
Left-sided 192 (68.8) 47 (67.1)
Missing 3 (1.1) –
Chemotherapy regimen 0.875
Capecitabine 59 (21.1) 13 (18.6)
CAPOX 190 (68.1) 50 (71.4)
FOLFOX/Other 27 (9.7) 7 (10.0)
Missing 3 (1.1) –
Number of comorbidities 0.980
Mean (SD) 2.33 (1.78) 2.33 (2.00)
Marital status 0.369
Married/domestic partnership 207 (74.2) 49 (70.0)
Unmarried/divorced/widowed 68 (24.4) 21 (30.0)
Missing 4 (1.4) –
Number of persons in household 0.615
1 49 (17.6) 13 (18.6)
2 177 (63.4) 42 (60.0)
3 23 (8.2) 4 (5.7)
> 3 26 (9.3) 11 (15.7)
Missing 4 (1.4) –
Educationb *0.041
Low 17 (6.1) 2 (2.9)
Middle 184 (65.9) 39 (55.7)
High 72 (25.8) 29 (41.4)
Missing 6 (2.2) 0 (0)
Currently working 0.949
Yes 65 (23.3) 16 (22.9)
No/retired 210 (75.3) 54 (77.1)
Missing 4 (1.4) –
Time from diagnosis primary tumor until start study 0.848
< 1.5 months 94 (33.7) 22 (31.4)
1.5–10 months 89 (31.9) 25 (35.7)
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Table 1 Results of univariable analyses on demographic, clinical and psychosocial baseline variables (Continued)
No use of psychosocial support
services (n = 279)(n,%)
Use of psychosocial support
services (n = 70)(n,%)
p-value
> 10 months 93 (33.3) 23 (32.9)
Missing 3 (1.1) –
Time from diagnosis metastatic disease until start study 0.666
< 1.0 months 95 (34.1) 27 (38.6)
1.0–2.5 months 87 (31.2) 23 (32.9)
> 2.5 months 94 (33.7) 20 (28.6)
Missing 3 (1.1) –
Prior cancer related treatment
No 85 (30.5) 23 (32.9) 0.699
Yes 194 (69.5 47 (67.1)
Prior treatment metastases
No 214 (76.7) 56 (80.0) 0.657
Yes 62 (22.2) 14 (20.0)
Missing 3 (1.1) –
Number of organs with metastases 0.599
Median 2 2
Total number of metastases
Median 11.5 13.0 0.877
Participation in other trials 0.718
No 170 (60.9) 41 (58.6)
Yes 109 (39.1) 29 (41.4)
HADS
Total score 9.10 (6.30) 11.17 (7.47) *0.020
Distress on HADS No 208 (74.6) 44 (62.9) *0.033
Yes 67 (24.0) 26 (37.1)
Missing 4 (1.4) –
DT/PL
DT score 4.33 (2.68) 4.75 (2.40) *0.242
Total of physical problems 5.78 (6.29) 7.37 (4.61) *0.020
Total of emotional problems 1.95 (2.11) 2.74 (2.57) *0.009
Need to talk to professional No 257 (92.1) 58 (82.9) *0.023
Yes 22 (7.9) 12 (17.1)
Quality of life (QLQ-C30)
Physical functioning 74.84 (20.30) 72.76 (21.88) 0.451
Role functioning 65.69 (30.70) 58.81 (30.13) *0.010
Emotional functioning 78.25 (18.12) 72.86 (21.41) *0.095
Cognitive functioning 89.44 (14.97) 86.90 (16.76) *0.219
Social functioning 78.08 (23.89) 69.05 (31.38) *0.010
Global QOL 63.77 (21.73) 60.00 (21.78) *0.197
Pain score 16.00 (23.75) 40.15 (26.57) *0.174
Fatigue score 25.00 (16.67) 45.08 (44.44) *0.009
Abbreviations: SD standard deviation, ECOG PS Eastern Cooperative Oncology Group Performance Status, HADS Hospital Anxiety and Depression Scale, DT/PL
Distress Thermometer and Problem list, QLQ-C30 Quality of Life Questionnaire-C30. *Characteristics were included in the multivariate model if they had an
univariable association (p ≤ .25). aECOG PS 0: Fully active, able to carry on all pre-disease performance without restriction. ECOG PS 1: Restricted in
physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work. ECOG PS 2:
Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours. bLow: primary education,
middle: lower general secondary education, intermediate vocational education or high school, high: higher vocational education or university
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their associations with the use of psychosocial support.
Patients in the group that used psychosocial services
were significantly younger at baseline and were more
often higher educated. In addition, they reported higher
levels of distress and were more frequently classified as
being distressed (i.e. a score of ≥13 on HADS), reported
more emotional and physical problems, and expressed
the need to talk to a professional more frequently. Fi-
nally, patients who used psychosocial services demon-
strated lower levels of role and social functioning at
baseline and were significantly more fatigued. There
were no differences for gender, marital status, employ-
ment, tumor burden or ECOG PS at baseline. Table 2
contains the univariable analyses for clinical events dur-
ing follow-up and their associations with the use of psy-
chosocial support. Patients in the group that used
psychosocial services were more often responding to
therapy within the first ten weeks of treatment (i.e.
stable disease or partial response), whereas patients who
did not use psychosocial services more often had had
progression of disease within the first ten weeks of
treatment.
Table 3 contains the regression parameters for the
baseline predictors retained in the backward logistic re-
gression analysis. Use of psychosocial services was asso-
ciated with younger age, presence of more pain (at
baseline), an expressed need to talk to a professional and
a higher educational level. The final model with baseline
characteristics had an overall classification rate of 81.2%
with Nagelkerke R2 statistic of 0.118. In Table 4 the final
model with baseline variables was used as a base and
contains the regression parameters for the variables
retained in the backward logistic regression analysis after
adding clinical factors during treatment. Combined with
the four baseline variables of the first model, patients
who had progressive disease within the first ten weeks of
treatment were less likely to use psychosocial services.
The final model combining selected baseline variables
and clinical variables over time had an overall classifica-
tion rate of 81.5% with Nagelkerke R2 statistic of 0.140.
Discussion
This study prospectively investigated the predictors for
use of psychosocial services in patients with mCRC re-
ceiving first line palliative treatment. Psychosocial sup-
port was broadly defined as contacts with social
workers, contacts with services in regional mental
healthcare organizations, contacts with psychiatrists/psy-
chologists in private practice, and contacts with psychia-
trists/psychologist in hospital settings. Our approach is
unique as we assessed and distinguished possible predic-
tors at baseline and clinical predictors during treatment.
In line with previously reported results [16], approxi-
mately one in five patients used psychosocial services at
any point during their 48-weeks clinical follow-up. In
this sample of patients with mCRC, those patients hav-
ing a younger age, having completed higher education
levels, indicating higher levels of pain and expressing the
need to talk to a professional were found to be more
likely to use psychosocial services. Furthermore, absence
of disease progression within the first ten weeks of treat-
ment was found to be a clinical predictor for the use of
these services.
The relationship between younger age and the use of
psychosocial services is consistent with previous re-
search [29–31]. A plausible explanation could be that
advanced disease may be more traumatic and require
greater life adjustments in younger patients who are in a
different phase of life with work, children and relation-
ships, compared to older patients [28, 31]. In addition,
younger patients may be more aware of psychosocial ser-
vices [28]. Users of psychosocial support in our study
were more likely to have completed higher levels of edu-
cation, a trend that is consistent with the literature [30,
32]. A knowledge gap may exist between patients with
different education levels, those with less education may
have greater information needs regarding the benefits
and availability of psychosocial services [32]. In line with
findings from O’Hea et al. [29], patients reporting more
pain were seen to use psychosocial services more often.
In agreement with our findings that showed that the
Table 2 Univariable analyses for clinical variables during treatment predictive for the use of psychosocial support services
No use of psychosocial support
services (n = 279)(n,%)
Use of psychosocial support
services (n = 70)(n,%)
p-value
Progression of disease within first 10 weeks of treatment *0.089
No 242 (86.7) 66 (94.3)
Yes 37 (13.3) 4 (5.7)
Progression of disease during follow up 0.289
No 93 (33.3) 28 (40.0)
Yes 186 (66.7) 42 (60.0)
Total number of grade 3–4 AEs during 48 weeks follow up 1.64 (2.12) 2.06 (2.65) *0.166
Total number of admissions during 48 weeks follow up 1.79 (1.34) 2.13 (1.98) *0.216
Abbreviations: AEs adverse events. *Characteristics were included in the multivariate model if they had an univariable association (p ≤ .25)
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expressed need to talk to a professional was a predictor
for use of psychosocial services, asking patients about
their desire for help to highlight who are willing to
accept psychosocial interventions has been proposed be-
fore as an efficient way of connecting patients to psycho-
social services [16, 33].
The lack of association between gender and marital
status and of use of psychosocial services contrasts with
previous studies [28, 29, 31, 34], in which female and
single patients have been shown to be using psychosocial
services more often. However, those results were ob-
tained mainly in heterogeneous study samples, predomi-
nated by younger, female patients suffering from breast
cancer. Our study involved a homogeneous sample of on
average older, mostly male mCRC patients, whose emo-
tional concerns and needs, or access to psychosocial care
services may have been different.
Absence of disease progression was associated with
higher use of psychosocial services, while disease pro-
gression itself has previously been shown to be an im-
portant predictor for psychological distress [14, 35]. One
hypothesis could be that patients’ focus when facing dis-
ease progression may shift towards end-of-life issues, in
which energy is more likely to be spent on preparation
for death and achieving a sense of completion than in
using psychosocial support services [36, 37].
Other clinical factors, such as burden of disease, time
since diagnosis (of metastasis), type of systemic treat-
ment, or amount of suffered high grade AEs and
subsequent admissions did not appear to be predictors.
Low predictive associations between clinical variables
and need for psychological support services were dem-
onstrated before [38]. These combined findings suggest
that clinical (both pre- and on-treatment) variables are
largely not predictive for use of psychosocial support,
and emphasize that patient sociodemographic character-
istics and self-report assessments of patients’ physical
and psychosocial well-being are essential in predicting
which patients will use psychosocial services.
In line with previous work [34, 38], our results demon-
strated that out of 93 patients who scored above the cut-
off for distress at baseline, fewer than one third used
psychosocial services. It has been demonstrated that the
majority of patients show strong resilience following
life-threatening events, characterized by transient symp-
toms of distress and return to normal levels without
need for psychosocial interventions [39, 40]. This kind
of emotional distress may even facilitate adaptation to
cancer [12]. A minority of distressed patients does not
seem to be able to cope with emotions related to cancer;
this group of patients may be in need for referral to spe-
cialized mental healthcare [12].
Even though expressing the need to talk to profes-
sionals was found to be predictive for use of psycho-
social services, out of 34 patients that expressed the
subjective need to talk to a professional, services were
only used by 12 (35.3%) of these patients. This latter
finding is concerning. In our study we did not further
Table 3 Final multivariable model of baseline predictors
Predictive factora Wald p-
value
Odds
Ratio
95% C.I.for EXP(B) VIF
Lower Upper
Need to talk to professional 4.451 .035 2.360 1.063 5.240 1.010
Pain score at baseline 8.053 .005 1.015 1.005 1.025 1.009
Age 8.066 .005 .963 .938 .988 1.022
Education 5.823 .054 1.031
Middle compared to low .084 .772 1.255 .270 5.837
High compared to low 1.340 .247 2.518 .527 12.024
Abbreviations: OR odds ratio, VIF variable inflation factor. aPredictive factors were statistically significant at the least at the 0.10 level
Table 4 Final multivariable model of baseline predictors and clinical predictors
Predictive factora Wald p-
value
Odds
Ratio
95% C.I.for EXP(B) VIF
Lower Upper
Need to talk to professional 4.712 .030 2.429 1.090 5.412 1.010
Pain score at baseline 9.895 .002 1.017 1.006 1.028 1.030
Age 6.938 .008 .965 .940 .991 1.030
Education 6.190 .045 1.033
Middle compared to low .128 .720 1.327 .283 6.229
High compared to low 1.558 .212 2.729 .564 13.204
Progression within first 10 weeks of treatment 4.136 .042 .314 .103 .959 1.029
Abbreviations: OR odds ratio, VIF variable inflation factor. aPredictive factors were statistically significant at the least at the 0.10 level
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investigate why patients with an expressed need did or
did not use support services. Known barriers to use of
psychosocial services are lack of knowledge, financial
constraints, lack of access, as well as lack of confidence
in and negative perceptions towards psychosocial ser-
vices [18, 41]. In order for those patients with a need for
support to actually access these services, future studies
should focus on the promotion of psychosocial support
services [42]. However, it is worth mentioning that the
item used to assess the need to talk to a professional
could have been interpreted differently by patients, as
there was no specific reference to mental health and this
need may have referred to various disciplines. In a re-
cently updated version of the Distress Thermometer, pa-
tients can now indicate with whom they would like to
talk followed by a list of both physical and psychosocial
healthcare providers [43].
Study limitations
Limitations of the present study include the self-reporting
of use of psychosocial services, that may have under- or
overestimated the actual use of these care services.
Self-reported data are argued to be less reliable and threat-
ened by bias arising from social desirability and recall
period [44]. Second, this study did not make a clear dis-
tinction between type of psychosocial needs and problems.
For some needs, especially needs resulting from practical
or logistical issues, psychosocial services may not be ap-
propriate. In addition, the analyses were conducted on a
homogenous sample of particularly middle-aged, male, pa-
tients with advanced CRC participating in a CRT. Further
research is needed to determine whether these findings
apply to community-based settings as well and whether
these findings are generalizable to younger or older pa-
tients. Furthermore, the need for psychosocial support
was assessed with one single item question only. Another
limitation was the sample size. Even though a total of 349
patients participated in the original trial, only 70 made use
of psychosocial support. As a consequence some of the
subgroups only contained a small number of patients,
which could limit the generalizability of the results, war-
ranting external validation.
Clinical implications
Our results can be used to inform clinicians in interven-
tion practices as these provide insight into characteris-
tics of patients receptive to psychosocial care.
Identification of predictors for use of psychosocial ser-
vices in patients with mCRC may allow resources to be
directed more efficiently to patients who need and want
help. In addition, our study findings underscore that
relying on screening for distress to identify patients that
use psychosocial services is less successful than has been
assumed [33]: the need to talk to a professional, instead
of the level of distress, predicted use of psychosocial ser-
vices. Instead of relying on screening for distress, psy-
chosocial services could be targeted to patients
expressing the need to talk to a professional. This could
be supplemented with more targeted assessments of pa-
tients at risk for psychosocial problems [45]. In addition,
it should be emphasized that there may be a group of in-
dividuals at risk of suffering from negative psychosocial
outcomes that is unlikely to use psychosocial services
(e.g. less educated, older man), future research should
focus on potential barriers to this use and on novel tar-
geting tools to include these patients that my benefit
from support.
Conclusions
To conclude, approximately 20% of patients with mCRC
starting with first line palliative treatment used psycho-
social services during 48 weeks of follow up. The follow-
ing predictors for use of psychosocial support were
identified: being younger, reporting higher levels of pain,
being higher educated, expressing a need to talk to a
professional and the absence of progressive disease
within the first weeks of treatment. These findings con-
tribute to the understanding of factors that determine
the need for psychosocial services.
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